Watch for Dosing Confusion with Ceftolozane/Tazobactam

March 2015

Please see the FDA safety warning (May 2015) concerning dose confusion/medication errors associated with Zerbaxa

Reps will be promoting a new IV anti-infective, ceftolozane/tazobactam (Zerbaxa).

Ceftolozane/tazobactam is approved for complicated UTIs (cUTIs) and intra-abdominal infections (cIAIs) in adults...and higher doses are still being studied for ventilator-associated pneumonia.

Think of it as primarily covering gram-negative bacteria...including Pseudomonas and ESBL-producing Enterobacteriaceae.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote